Propellant manufacturer Honeywell and CDMO Recipharm are partnering on development of MDIs formulated with Honeywell’s Solstice Air lower-GWP propellant, the companies said. Honeywell announced in October 2022 that it had started large scale manufacturing of medical grade Solstice Air HFO-1234ze(e) for use in metered dose inhalers and has previously announced a partnership with AstraZeneca for development of MDIs formulated with the propellant. In April 2022, Recipharm launched services for companies transitioning their MDIs from HFA to lower-GWP propellants such as HFA 152a and HFO 1234ze.
Honeywell VP and General Manager, Honeywell Foam and Industrial Products, Laura Reinhard commented, “Honeywell is making great strides to offer patients who rely on pMDIs a lower greenhouse gas solution to meet their medical needs. Through our collaboration with Recipharm, the increased use of near-zero GWP propellant used in pMDIs will help reduce the environmental impact of the life-saving medical treatments patients need, without sacrificing performance.”
Recipharm President of Advanced Delivery Systems Chris Hirst said, “As the first CDMO to partner with Honeywell for use of Solstice Air, this collaboration significantly accelerates and simplifies our customers’ pathway to develop the next generation of low greenhouse gas pMDIs. Our collaboration is supported by Recipharm’s investment in manufacturing with HFO-1234ze(E) cGMP at our Holmes Chapel, United Kingdom site, and the further development of the Bespak valve range to ensure the required product performance.”
Read the Honeywell and Recipharm press release.
